ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc., (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) clearance of the 7F Proxis™ Embolic Protection System. The Proxis Embolic Protection System is intended to extract debris that may become dislodged when an intervention, such as delivering a stent, is performed on patients who have previously undergone a heart bypass procedure using a saphenous vein graft (SVG). The Proxis Embolic Protection System is the first FDA cleared embolic protection system to provide protection proximally, or “upstream,” from an SVG blockage.
